Home > Rheumatology > EULAR 2019 > Psoriatic Arthritis > Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients with PsA

Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients with PsA

Presented By
Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA
Conference
EULAR 2019

In a head-to-head comparison of the 2 drugs, it was concluded that ixekizumab showed superior efficacy to adalimumab, based on simultaneous achievement of ACR50 and PASI100 responses in week 24, in biologic-naïve patients with active psoriatic arthritis (PsA) and skin disease. Greater improvements with ixekizumab versus adalimumab were also attained in individual PsA domains and composite treat-to-target outcomes.

TNF inhibitors (TNFi) like adalimumab are frequently prescribed in patients receiving biologic treatment. However, a significant number of patients with PsA have insufficient response or become intolerant to TNFi therapy [1]. Therefore, therapies with an alternative mechanism of action and with long-term efficacy and safety are important for patients with PsA. IL-17A is a pro-inflammatory cytokine involved in the pathophysiology of PsA [2]. Ixekizumab is a high affinity monoclonal antibody that selectively targets IL-17A [3].

Dr Philip Mea...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on